English to Russian Medical Medical: Pharmaceuticals

Data from this clinical trial firmly confirm that the qHPV vaccine is highly efficacious at preventing lower genital tract disease in women up to age 45 years as based on the final 4-year data.
Efficacy estimates against the combined incidence of persistent infection, CIN, or EGL related to vaccine HPV types in the PPE and NRT populations were 88.7% (95% CI: 78.1, 94.8) and 79.9% (95% CI: 69.4, 87.3), respectively.

Although the observed efficacy of most end points was largely comparable with previous evaluations in this population (Munoz et al, 2009), there were exceptions, particularly for the HPV 16- and 18-related end points in the ITT population (Table 2).
These newly significant efficacy results are likely the result of additional follow-up and *end point accrual*.
The extra end points accrued during the 1.6 additional years of follow-up increased precision of the efficacy estimates when compared with those previously reported (Munoz et al, 2009).